mitochondrial ribosomal protein S6 pseudogene 2Genealiases: []
Q-omics provides the consensus-scored MRPS6P2 profile across patient tissues and cancer cell-line models. MRPS6P2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, MRPS6P2 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, MRPS6P2 RNA expression shows 9,980 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, KIRC, and LSCC as cancer lineages where MRPS6P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MRPS6P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MRPS6P2 survival associations across molecular data types. MRPS6P2 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MRPS6P2 RNA expression–survival associations across cancer types. High MRPS6P2 expression shows unfavorable associations in UVM, THYM, UCEC, KICH and KIRC, but favorable associations in OV. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for MRPS6P2 RNA expression.
This table summarizes MRPS6P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MRPS6P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MRPS6P2 shows lower tumor expression in KIRC and KICH and higher tumor expression in LUAD and HNSC. The KIRC box plot shows higher MRPS6P2 RNA expression in normal versus tumor tissue (log2 FC = −0.052, t-test p < 0.001).
This table shows molecular features associated with MRPS6P2 in patient tissues and cancer cell lines. In patient samples, MRPS6P2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
